AOne-Year Open-Label Trial of Risperidone Augmentation in Lithium Nonresponder Youth with Preschool-Onset Bipolar Disorder

Abstract

A substantial proportion of youth with a history of preschool-onset BD treated with lithium were either nonresponders or partial responders. Subsequent augmentation of lithium with risperidone in these cases was well tolerated and efficacious. Potential predictors of lithium nonresponse identified in this study may guide the choice of medications earlier in the treatment process.